although much of the talk is surrounded around erivedge i believe the biggest and fastest way to double digits is cudc 907. go take a look and read up on infi and its rise from 6 to high 30's. 907 is now in patients so we might find out about toxicities fairly soon (hopefully nothing too bad) 907 could be very exciting and we own it so hopefully management keeps us informed. i feel that doing due diligence on 907 right now is more important thn E. read up on pi3k and hdac and blood cancers. seems like a legit approach. im still real curious about the lung trial with E.
Must be about growing up Aesop's fables or something similar, I have always a bird in hand kind of guy. Since you are trying to make the rest of us work harder, I actually e-mailed Genentech today about when we can expect update for OBCC trial (NCT01201915). One thing about this trial is they are bound to learn to administer the drug better which might actually increase applications. We'll see.
thx for doing dd on that. let us know what you find out. while operable could heat things up being the sole owner of 907 would give us a ton of leverage if we start to get some whispers of efficacy. check out pcyc too. also look at lil kerx,,, every dog has its day. hopefully ours happens soon.